Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20

Vaccine

Volumn 33, Issue 30, 2015, Pages 3518-3525

  Galliher Beckley, Amy ^a   Li, Xiangdong ^a   Bates, John T ^a   Madera, Rachel ^a   Waters, Andrew ^a   Nietfeld, Jerome ^a   Henningson, Jamie ^a   He, Dongsheng ^b   Feng, Wenhai ^c   Chen, Ruiai ^b   Shi, Jishu ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Highly pathogenic PRRS virus; JXA 1; NADC 20; Pig; Vaccine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 8; LIVE VACCINE; NEUTRALIZING ANTIBODY; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE; RNA VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL PIG; FEVER; HUMORAL IMMUNITY; IMMUNIZATION; NONHUMAN; NORTH AMERICAN; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION; VIRUS LOAD; VIRUS STRAIN; VIRUS TITRATION; WEIGHT GAIN; ANIMAL; BLOOD; CHINA; IMMUNOLOGY; LUNG; PATHOLOGY; PIG; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VIREMIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHINA; INTERFERON-ALPHA; INTERFERON-BETA; LUNG; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME; PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS; SEVERITY OF ILLNESS INDEX; SWINE; TIME FACTORS; TREATMENT OUTCOME; VACCINES, ATTENUATED; VIRAL LOAD; VIRAL VACCINES; VIREMIA;

EID: 84937191727     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.058     Document Type: Article

References (43)

1. Holtkamp D.J., Kliebenstein J.B., Neumann E.J., Zimmerman J.J., Rotoo H.F., Yoder T.K., et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod 2013, 21(2):72084.
2. Collins J.E., Benfield D.A., Christianson W.T., Harris L., Hennings J.C., Shaw D.P., et al. Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR-2332) in North America and experimental reproduction of the disease in gnotobiotic pigs. J Vet Diagn Invest 1992, 4(2):117-126.
3. Li X., Galliher-Beckley A., Nietfeld J.C., Faaberg K.S., Shi J. MontanideTM Gel01 ST Adjuvant Enhances PRRS Modified Live Vaccine Efficacy by Regulating Porcine Humoral and Cellular Immune Responses. World J Vaccines 2013, 3(1):1-9.
4. Charerntantanakul W. Porcine reproductive and respiratory syndrome virus vaccines: immunogenicity, efficacy and safety aspects. World J Virol 2012, 1(1):23-30.
5. Li X., Galliher-Beckley A., Pappan L., Trible B., Kerrigan M., Beck A., et al. Comparison of host immune responses to homologous and heterologous type II porcine reproductive and respiratory syndrome virus (PRRSV) challenge in vaccinated and unvaccinated pigs. Biomed Res Int 2014, 2014:416727.
6. Meng X.J. Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development. Vet Microbiol 2000, 74(4):309-329.
7. Harms P.A., Sorden S.D., Halbur P.G., Bolin S.R., Lager K.M., Morozov I., et al. Experimental reproduction of severe disease in CD/CD pigs concurrently infected with type 2 porcine circovirus and porcine reproductive and respiratory syndrome virus. Vet Pathol 2001, 38(5):528-539.
8. Calzada-Nova G., Husmann R.J., Schnitzlein W.M., Zuckermann F.A. Effect of the host cell line on the vaccine efficacy of an attenuated porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 2012, 148(1-2):116-125.
9. Ni Y.Y., Opriessnig T., Zhou L., Cao D., Huang Y.W., Halbur P.G., et al. Attenuation of porcine reproductive and respiratory syndrome virus by molecular breeding of virus envelope genes from genetically divergent strains. J Virol 2013, 87(1):304-313.
10. Tian K., Yu X., Zhao T., Feng Y., Cao Z., Wang C., et al. Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS ONE 2007, 2(6):e526.
11. Ni J., Yang S., Bounlom D., Yu X., Zhou Z., Song J., et al. Emergence and pathogenicity of highly pathogenic Porcine reproductive and respiratory syndrome virus in Vientiane: Lao People's Democratic Republic. J Vet Diagn Invest 2012, 24(2):349-354.
12. Tian Z.J., An T.Q., Zhou Y.J., Peng J.M., Hu S.P., Wei T.C., et al. An attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) protects piglets against HP-PRRS. Vet Microbiol 2009, 138(1-2):34-40.
13. Han W., Wu J.J., Deng X.Y., Cao Z., Yu X.L., Wang C.B., et al. Molecular mutations associated with the in vitro passage of virulent porcine reproductive and respiratory syndrome virus. Virus Genes 2009, 38(2):276-284.
14. Yu X., Chen N., Deng X., Cao Z., Han W., Hu D., et al. Genomic sequencing reveals mutations potentially related to the overattenuation of a highly pathogenic porcine reproductive and respiratory syndrome virus. Clin Vaccine Immunol 2013, 20(4):613-619.
15. Leng X., Li Z., Xia M., He Y., Wu H. Evaluation of the efficacy of an attenuated live vaccine against highly pathogenic porcine reproductive and respiratory syndrome virus in young pigs. Clin Vaccine Immunol 2012, 19(8):1199-1206.
16. Guo B., Lager K.M., Henningson J.N., Miller L.C., Schlink S.N., Kappes M.A., et al. Experimental infection of United States swine with a Chinese highly pathogenic strain of porcine reproductive and respiratory syndrome virus. Virology 2013, 435(2):372-384.
17. Lowe J., Gauger P., Harmon K., Zhang J., Connor J., Yeske P., et al. Role of transportation in spread of porcine epidemic diarrhea virus infection: United States. Emerg Infect Dis 2014, 20(5):872-874.
18. Tian P.F., Jin Y.L., Xing G., Qv L.L., Huang Y.W., Zhou J.Y. Evidence of recombinant strains of porcine epidemic diarrhea virus: United States, 2013. Emerg Infect Dis 2014, 20(10):1735-1738.
19. Vlasova A.N., Marthaler D., Wang Q., Culhane M.R., Rossow K.D., Rovira A., et al. Distinct characteristics and complex evolution of PEDV strains: North America, May 2013-February 2014. Emerg Infect Dis 2014, 20(10):1620-1628.
20. Li X., Galliher-Beckley A., Huang H., Sun X., Shi J. Peptide nanofiber hydrogel adjuvanted live virus vaccine enhances cross-protective immunity to porcine reproductive and respiratory syndrome virus. Vaccine 2013, 31(41):4508-4515.
21. Wang L., Hou J., Zhang H., Feng W.H. Complete genome sequence of a novel highly pathogenic porcine reproductive and respiratory syndrome virus variant. J Virol 2012, 86(23):13121.
22. Lianghai W., Jun H., Li G., Xue-kun G., Zhibin Y., Yaohua Z., et al. Attenuation of highly pathogenic porcine reproductive and respiratory syndrome virus by inserting an additional transcription unit. Vaccine 2014, 32(43):57405748.
23. Jackson P.G.G., Cockcroft P.D. The handbook of pig medicine 2007, Elsevier Ltd, New York, NY.
24. Lopez O.J., Oliveira M.F., Garcia E.A., Kwon B.J., Doster A., Osorio F.A. Protection against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent. Clin Vaccine Immunol 2007, 14(3):269275.
25. Halbur P.G., Paul P.S., Frey M.L., Landgraf J., Eernisse K., Meng X.J., et al. Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet Pathol 1995, 32(6):648-660.
26. Wang L., Hou J., Gao L., Guo X.K., Yu Z., Zhu Y., et al. Attenuation of highly pathogenic porcine reproductive and respiratory syndrome virus by inserting an additional transcription unit. Vaccine 2014, 32(43):5740-5748.
27. Lager K.M., Schlink S.N., Brockmeier S.L., Miller L.C., Henningson J.N., Kappes M.A., et al. Efficacy of Type 2 PRRSV vaccine against Chinese and Vietnamese HP-PRRSV challenge in pigs. Vaccine 2014, 32(48):6457-6462.
28. An T.Q., Tian Z.J., Xiao Y., Li R., Peng J.M., Wei T.C., et al. Origin of highly pathogenic porcine reproductive and respiratory syndrome virus: China. Emerg Infect Dis 2010, 16(2):365-367.
29. Yu X., Zhou Z., Cao Z., Wu J., Zhang Z., Xu B., et al. Assessment of the safety and efficacy of an attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV). Clin Vaccine Immunol 2015, 22(May (5)):493-502.
30. Zhou L., Ni Y.Y., Pineyro P., Cossaboom C.M., Subramaniam S., Sanford B.J., et al. Broadening the heterologous cross-neutralizing antibody inducing ability of porcine reproductive and respiratory syndrome virus by breeding the GP4 or M genes. PLoS ONE 2013, 8(6):e66645.
31. Ranjni J.C., Benjamin R.T., Raymond R.R.R. Pathogenesis of porcine reproductive and respiratory syndrome virus. Curr Opin Virol 2012, 2(3):256-263.
32. Yongming S., Raymond R.R.R., Frank B. Interaction between innate immunity and porcine reproductive and respiratory syndrome virus. Anim Health Res Rev 2011, 12(02):149167.
33. Wang R., Zhang Yan-Jin Antagonizing interferon-mediated immune response by porcine reproductive and respiratory syndrome virus. Biomed Res Int 2014, 2014. Article ID 315470, 9 pages.
34. Wissink E.H.J., Wijk H.A.R.v., Kroese M.V., Weiland E., Meulenberg J.J.M., Rottier P.J.M., et al. The major envelope protein, GP5, of a European porcine reproductive and respiratory syndrome virus contains a neutralization epitope in its N-terminal ectodomain. J Gen Virol 2003, 84(6):1535-1543.
35. Plagemann P.G.W., Rowland R.R.R., Faaberg K.S. The primary neutralization epitope of porcine respiratory and reproductive syndrome virus strain VR-2332 is located in the middle of the GP5 ectodomain. Arch Virol 2002, 147(12):2327-2347.
36. Ostrowski M., Galeota J.A., Jar A.M., Platt K.B., Osorio F.A., Lopez O.J. Identification of Neutralizing and Nonneutralizing Epitopes in the Porcine Reproductive and Respiratory Syndrome Virus GP5 Ectodomain. J Virol 2002, 76(9):42414250.
37. Thaa B., Sinhadri B.C., Tielesch C., Krause E., Veit M. Signal peptide cleavage from GP5 of PRRSV: a minor fraction of molecules retains the decoy epitope, a presumed molecular cause for viral persistence. PLoS ONE 2013, 8(6). e65548.
38. Zuzhang W., Tao L., Lichang S., Yanhua L., Xiaoming W., Fei G., et al. N-Linked glycosylation of GP5 of porcine reproductive and respiratory syndrome virus is critically important for virus replication in vivo. J Virol 2012, 86(18):9941-9951.
39. Hiep L.X.V., Byungjoon K., Kyoung-Jin Y., William W.L., Asit K.P., Fernando A.O. Immune evasion of porcine reproductive and respiratory syndrome virus through glycan shielding involves both Glycoprotein 5 as well as Glycoprotein 3. J Virol 2011, 85(11):5555-5564.
40. Israrul H.A., Byungjoon K., Fernando A.O., Asit K.P. Influence of N-linked glycosylation of porcine reproductive and respiratory syndrome virus GP5 on virus infectivity, Antigenicity, and ability to induce neutralizing antibodies. J Virol 2006, 80(8):39944004.
41. Won-Il K., Jae-Jo K., Sang-Ho C., Wai-Hong W., Vickie C., Rich E., et al. Significance of genetic variation of PRRSV ORF5 in virus neutralization and molecular determinants corresponding to cross neutralization among PRRS viruses. Vet Microbiol 2013, 162(1):1022.
42. Jung-Ah L., Byungjoon K., Fernando A.O., Asit K.P., Nak-Hyung L., Sang-Won L., et al. Protective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5. Vaccine 2014, 32(29):36173622.
43. Trujillo J.D., Kumpula-McWhirter N.M., Hotzel K.J., Gonzalez M., Cheevers W.P. Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses. J Virol 2004, 78(17):9190-9202.